ATE322893T1 - Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten - Google Patents

Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten

Info

Publication number
ATE322893T1
ATE322893T1 AT96921540T AT96921540T ATE322893T1 AT E322893 T1 ATE322893 T1 AT E322893T1 AT 96921540 T AT96921540 T AT 96921540T AT 96921540 T AT96921540 T AT 96921540T AT E322893 T1 ATE322893 T1 AT E322893T1
Authority
AT
Austria
Prior art keywords
inhibitor
cyclooxygenase
leucotrien
agents containing
hydrolase
Prior art date
Application number
AT96921540T
Other languages
English (en)
Inventor
Peter C Isakson
Gary D Anderson
Susan A Gregory
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE322893T1 publication Critical patent/ATE322893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96921540T 1995-06-12 1996-06-11 Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten ATE322893T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/489,468 US5700816A (en) 1995-06-12 1995-06-12 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Publications (1)

Publication Number Publication Date
ATE322893T1 true ATE322893T1 (de) 2006-04-15

Family

ID=23943995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921540T ATE322893T1 (de) 1995-06-12 1996-06-11 Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten

Country Status (9)

Country Link
US (2) US5700816A (de)
EP (1) EP0843549B1 (de)
JP (1) JPH11507925A (de)
AT (1) ATE322893T1 (de)
AU (1) AU6274496A (de)
CA (1) CA2224379A1 (de)
DE (1) DE69636036T2 (de)
ES (1) ES2262156T3 (de)
WO (1) WO1996041625A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10504542A (ja) * 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0833664A1 (de) * 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ES2243978T3 (es) * 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
CA2246265A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
PT880363E (pt) * 1996-02-13 2002-12-31 Searle & Co Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US6110944A (en) * 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
US6162823A (en) * 1997-03-12 2000-12-19 G.D. Searle & Co. LTA4 hydrolase inhibitors
BR9807920A (pt) * 1997-04-03 2000-02-22 Searle & Co Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
DE69810938T2 (de) * 1997-04-11 2003-11-06 Grelan Pharmaceutical Co., Ltd. Pyrazolderivate und sie enthaltende cox-inhibitoren
WO1998047509A1 (en) * 1997-04-18 1998-10-29 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
CA2303152A1 (en) 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US7189703B2 (en) 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
JP4234907B2 (ja) * 1998-05-15 2009-03-04 わかもと製薬株式会社 抗炎症点眼剤
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
DE69915519T2 (de) 1999-02-27 2005-02-03 Glaxo Group Ltd., Greenford Pyrazolopyridine
US6376519B1 (en) 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
DE60112609T2 (de) * 2000-12-15 2006-01-19 Glaxo Group Ltd., Greenford Pyrazolopyridine
US7163940B2 (en) * 2000-12-15 2007-01-16 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
JP4092203B2 (ja) * 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
ES2227451T3 (es) * 2001-03-08 2005-04-01 Smithkline Beecham Corporation Derivados de pirazolopiridina.
JP4237497B2 (ja) * 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
JP2004525150A (ja) * 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
WO2002083672A1 (en) * 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
EP1385847B1 (de) * 2001-04-27 2005-06-01 SmithKline Beecham Corporation Pyrazolo[1,5]pyridinderivate
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
IL158667A0 (en) * 2001-06-21 2004-05-12 Smithkline Beecham Corp Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP1423389B1 (de) * 2001-09-07 2007-06-06 SmithKline Beecham Corporation Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
ES2262893T3 (es) * 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
US7199120B2 (en) * 2001-12-11 2007-04-03 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
AU2003225964B2 (en) * 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
AU2003245295B2 (en) * 2002-05-20 2008-01-03 Collagenex Pharmaceuticals, Inc. Methods of treating allergic reactions
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US7153863B2 (en) * 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
CA2502357A1 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
DK1622630T3 (da) * 2003-05-07 2012-12-17 Osteologix As P009368epdk1
ATE342722T1 (de) * 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
US20050272051A1 (en) * 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
EP1568369A1 (de) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004027912A1 (de) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
NZ567627A (en) * 2005-09-30 2011-08-26 Boehringer Ingelheim Vetmed Granulation process for making a divisible tablet containing meloxicam
BRPI0707338A2 (pt) * 2006-01-30 2011-05-03 Transtech Pharma Inc derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
AU2008274941A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
EP2336125B1 (de) * 2008-04-11 2013-01-09 Janssen Pharmaceutica N.V. Thiazolopyridin-2-yloxy-phenyl- und Thiazolopyrazin-2-yloxy-phenyl-amine als Modulatoren von Leukotrien-A4-hydrolase
US8399465B2 (en) 2009-05-14 2013-03-19 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
WO2011046853A1 (en) * 2009-10-12 2011-04-21 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN105622422B (zh) * 2016-01-29 2017-12-05 南开大学 一类溴代六氢茚酮类化合物及其制备方法和用途
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745427A (en) * 1985-09-13 1988-05-17 Minolta Camera Kabushiki Kaisha Multi-point photometric apparatus
US4912131A (en) * 1987-06-18 1990-03-27 Merck Frosst Canada, Inc. 4,7-diacyloxybenzofuran derivatives
US4778805A (en) * 1987-06-18 1988-10-18 Merck Frosst Canada 4,7-benzofurandione derivatives useful as inhibitors of leukotriene synthesis
EP0360246B1 (de) * 1988-09-21 1994-03-30 G.D. Searle & Co. 3-Oxiranbenzoesäuren und Derivate
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
US5455271A (en) * 1992-06-18 1995-10-03 The Scripps Research Institute Tight-binding inhibitors of leukotriene A4 hydrolase
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) * 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) * 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
RU2139281C1 (ru) * 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) * 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Also Published As

Publication number Publication date
US5990148A (en) 1999-11-23
AU6274496A (en) 1997-01-09
CA2224379A1 (en) 1996-12-27
US5700816A (en) 1997-12-23
EP0843549B1 (de) 2006-04-12
DE69636036T2 (de) 2006-12-07
JPH11507925A (ja) 1999-07-13
EP0843549A1 (de) 1998-05-27
WO1996041625A1 (en) 1996-12-27
DE69636036D1 (de) 2006-05-24
ES2262156T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
DE69635048D1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
DE69615247D1 (de) Vorrichtung zum Ein- und Ausgeben von Wertpapieren
ATE147618T1 (de) Kosmetisches und/oder dermatologisches mittel enthaltend thermal- oder mineralwasser und einen gegen akne oder älterung aktiven agentsien
ZA948169B (en) Peptidyl derivatives and processes for their preparation
GEP20001970B (en) Herbicidal Benzoyl Derivatives
SE9703693D0 (sv) Novel combination
ATE404667T1 (de) Chromatin-regulatorgene
DE69003650D1 (de) Aloewasser, herstellungsverfahren und mittel, die dieses enthalten.
FR2720636B1 (fr) Compositions cosmétiques photoprotectrices contenant des huiles spécifiques et utilisations.
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
HUP9600424A2 (en) Novel retinoids and pharmaceutical compns. contg. them
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
DE69727711D1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
NO973473L (no) Astaxantinsuspensjon
EP0938898A3 (de) Behandlung von Pruritus
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
FR2723848B1 (fr) Composition cosmetique ou dermatologique contenant des extraits vegetaux encapsules
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
IL139303A0 (en) Treatment of arthritis and other similar conditions
DE69710752D1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
FI932651A7 (fi) Bacillus sp. MF12:sta saatavat alkaliset proteaasit, menetelmä niiden valmistamiseksi ja niiden käyttö
Hell the blink of an eye
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties